Last reviewed · How we verify

NCT06745297

A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated

Recruiting now Phase 1 Last updated 21 November 2025
What this trial tests

Phase 1 trial testing BI 3776528 in Healthy in 142 participants. Currently enrolling.

Timeline
23 January 2025
Primary endpoint
25 August 2026
25 August 2026

Quick facts

Lead sponsorBoehringer Ingelheim
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingsingle
Primary purposetreatment
Enrollment142
Start date23 January 2025
Primary completion25 August 2026
Estimated completion25 August 2026
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Boehringer Ingelheim — full company profile →

Who can join

Adults 18 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Boehringer Ingelheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06745297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing